Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDA NASDAQ:NGNE NASDAQ:PYXS NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.51-2.5%$8.18$6.50▼$9.35$442.79M0.8354,777 shs49,827 shsNGNENeurogene$26.14-5.1%$25.44$14.65▼$37.27$435.18M1.69132,203 shs107,404 shsPYXSPyxis Oncology$1.71-4.5%$1.79$0.97▼$5.55$113.41M1.42761,205 shs479,789 shsUPBUpstream Bio$7.25-10.3%$9.17$7.18▼$33.68$439.71M1.1515,950 shs632,081 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada-1.41%-1.66%-6.21%-13.77%+12.90%NGNENeurogene-2.82%-0.61%+2.57%+25.24%+60.02%PYXSPyxis Oncology-0.56%-8.67%+4.07%+25.17%+47.93%UPBUpstream Bio-3.35%-3.46%-14.04%+9.78%-11.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.51-2.5%$8.18$6.50▼$9.35$442.79M0.8354,777 shs49,827 shsNGNENeurogene$26.14-5.1%$25.44$14.65▼$37.27$435.18M1.69132,203 shs107,404 shsPYXSPyxis Oncology$1.71-4.5%$1.79$0.97▼$5.55$113.41M1.42761,205 shs479,789 shsUPBUpstream Bio$7.25-10.3%$9.17$7.18▼$33.68$439.71M1.1515,950 shs632,081 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada-1.41%-1.66%-6.21%-13.77%+12.90%NGNENeurogene-2.82%-0.61%+2.57%+25.24%+60.02%PYXSPyxis Oncology-0.56%-8.67%+4.07%+25.17%+47.93%UPBUpstream Bio-3.35%-3.46%-14.04%+9.78%-11.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 3.00Buy$12.0059.79% UpsideNGNENeurogene 2.86Moderate Buy$74.17183.73% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83299.61% UpsideUPBUpstream Bio 2.40Hold$38.75434.48% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, UPB, KMDA, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/14/2026UPBUpstream Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$51.00 ➝ $50.005/6/2026UPBUpstream Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$69.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026NGNENeurogene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026NGNENeurogene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.003/27/2026UPBUpstream Bio EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ In-Line$15.003/24/2026PYXSPyxis Oncology Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.00(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$180.46M2.39$0.60 per share12.61$4.68 per share1.60NGNENeurogene$930K444.10N/AN/A$17.10 per share1.53PYXSPyxis Oncology$13.86M7.82N/AN/A$0.86 per share1.99UPBUpstream Bio$2.85M138.44N/AN/A$6.29 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$20.20M$0.3521.4612.310.7111.21%7.73%5.41%8/12/2026 (Estimated)NGNENeurogene-$90.35M-$4.55N/AN/AN/AN/A-37.88%-34.70%8/10/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.31N/AN/AN/AN/A-135.60%-85.00%8/13/2026 (Estimated)UPBUpstream Bio-$143.44M-$2.91N/AN/AN/A-4,718.96%-43.82%-42.27%8/5/2026 (Estimated)Latest PYXS, UPB, KMDA, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/14/2026Q1 2026PYXSPyxis Oncology-$0.35-$0.37-$0.02-$0.37$0.02 millionN/A5/13/2026Q1 2026UPBUpstream Bio-$0.73-$0.7470-$0.0170-$0.75$1.03 million$1.03 million5/12/2026Q1 2026NGNENeurogene-$1.2963-$1.39-$0.0938-$1.39N/AN/A3/26/2026Q4 2025UPBUpstream Bio-$0.73-$0.7860-$0.0560-$0.78$0.52 million$0.67 million3/24/2026Q4 2025NGNENeurogene-$1.20-$1.12+$0.08-$1.13N/AN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/11/2026Q4 2025KMDAKamada$0.09$0.06-$0.03$0.06$145.07 million$44.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamada$0.192.53%N/A54.29%N/ANGNENeurogeneN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ALatest PYXS, UPB, KMDA, and NGNE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/11/2026KMDAKamadaannual$0.253.05%3/23/20263/23/20264/7/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A3.331.90NGNENeurogeneN/A13.0813.08PYXSPyxis OncologyN/A2.762.76UPBUpstream BioN/A23.1423.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%NGNENeurogene52.37%PYXSPyxis Oncology39.07%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipKMDAKamada36.10%NGNENeurogene11.68%PYXSPyxis Oncology10.60%UPBUpstream Bio16.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.51 million36.75 millionOptionableNGNENeurogene9015.80 million13.96 millionOptionablePYXSPyxis Oncology6063.35 million56.64 millionOptionableUPBUpstream Bio3854.42 million45.46 millionN/APYXS, UPB, KMDA, and NGNE HeadlinesRecent News About These CompaniesUpstream Bio: The Reset Is The Opportunity, Initiating At BuyMay 29, 2026 | seekingalpha.comUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at ...May 18, 2026 | markets.businessinsider.comUpstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid AsthmaMay 18, 2026 | quiverquant.comQUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International ConferenceMay 18, 2026 | globenewswire.comLifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)May 17, 2026 | theglobeandmail.comUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesMay 13, 2026 | zacks.comUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13, 2026 | globenewswire.comUpstream Bio, Inc. $UPB Shares Bought by UBS Group AGMay 7, 2026 | marketbeat.comJennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPBMay 3, 2026 | marketbeat.comUpstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vorApril 17, 2026 | de.investing.comUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceApril 17, 2026 | globenewswire.comUpstream Bio (UPB) price target decreased by 10.31% to 44.37April 10, 2026 | msn.comValidating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–RewardApril 7, 2026 | tipranks.comTruist senkt Kursziel für Upstream Bio wegen verzögertem StudienzeitplanApril 2, 2026 | de.investing.comEvercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herabMarch 27, 2026 | de.investing.comUpstream Bio plant Phase-3-Studien für Asthma-Medikament ab Q1 2027March 26, 2026 | de.investing.comUpstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | globenewswire.comUpstream Bio: CFO Gray veräußert Aktien im Wert von 7.915 US-DollarMarch 18, 2026 | de.investing.comUpstream Bio Reports Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal PolypsMarch 1, 2026 | quiverquant.comQUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingMarch 1, 2026 | globenewswire.comUpstream Bio präsentiert neue Studiendaten zu Verekitug auf AAAAI-KongressFebruary 26, 2026 | de.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Peloton Stock Gives Back Gains After Upbeat Earnings ReportBy Jennifer Ryan Woods | May 16, 2026PYXS, UPB, KMDA, and NGNE Company DescriptionsKamada NASDAQ:KMDA$7.51 -0.19 (-2.47%) Closing price 04:00 PM EasternExtended Trading$7.52 +0.00 (+0.07%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Neurogene NASDAQ:NGNE$26.14 -1.40 (-5.08%) Closing price 04:00 PM EasternExtended Trading$26.19 +0.05 (+0.19%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Pyxis Oncology NASDAQ:PYXS$1.71 -0.08 (-4.47%) Closing price 04:00 PM EasternExtended Trading$1.74 +0.03 (+1.46%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Upstream Bio NASDAQ:UPB$7.25 -0.83 (-10.27%) Closing price 04:00 PM EasternExtended Trading$7.30 +0.05 (+0.68%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
